ArticleDrug design, development and therapy2026
Paroxetine as a Therapeutic Agent in Inflammatory Osteolysis: Mechanistic Insights and Efficacy.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Inflammatory osteolysis is a common feature of numerous orthopedic conditions, primarily driven by excessive osteoclast formation and activation. Recent studies have demonstrated that paroxetine, a selective serotonin reuptake inhibitor commonly prescribed for mental disorders, has significant anti-inflammatory effects. However, its effects on inflammatory osteolysis have not been fully elucidated. In this study, we investigated the effects and underlying mechanisms of paroxetine on osteoclast differentiation and function as well as its influence on inflammatory osteolysis in a murine model. Methods: A mouse model of LPS-induced osteolysis was developed to assess the therapeutic efficacy of paroxetine in vivo. Utilizing the molecular structure of paroxetine, network pharmacology was used to predict principal targets and underlying mechanisms. The effect of paroxetine on osteoclast biology was subsequently investigated using morphological analysis, quantitative PCR (qPCR), and Western blotting. Results: The findings from animal experiments demonstrated that paroxetine effectively mitigated LPS-induced bone loss by inhibiting osteoclast differentiation. In vitro analyses revealed that paroxetine suppresses osteoclast formation and bone resorption in a dose-dependent manner. Mechanistically, paroxetine downregulated osteoclast-specific genes and proteins while concurrently inhibiting the NF-κB and PI3K-AKT signaling pathways. Additionally, network pharmacology analysis identified PIK3CA as a pivotal target, substantiated by molecular docking studies (binding energy of -8.0 kcal/mol) and rescue experiments employing PI3K (740 Y-P) and AKT (SC79) agonists, which reversed paroxetine-mediated inhibition of osteoclast formation. Conclusion: Paroxetine attenuated LPS-induced inflammatory osteolysis in mice and suppressed osteoclast differentiation and function in vitro, an effect associated with down-regulation of NF-κB and PI3K-AKT signaling. These data indicate that paroxetine may represent a potential therapeutic candidate for osteolytic bone diseases. However, further validation is required to confirm its efficacy and safety in more complex pre-clinical models and in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.